Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 3.6% - Time to Sell?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report)'s share price fell 3.6% during mid-day trading on Wednesday . The stock traded as low as $15.00 and last traded at $15.05. 157,665 shares traded hands during mid-day trading, an increase of 107% from the average session volume of 76,094 shares. The stock had previously closed at $15.61.Get Coeptis Therapeutics alerts:Analysts Set New Price TargetsSeparately, Weiss Ratings reissued a "sell (e+)" rating on shares of Coeptis Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of "Sell".Check Out Our Latest Research Report on Coeptis TherapeuticsCoeptis Therapeutics Stock Down 3.6%The stock has a market capitalization of $80.37 million, a price-to-earnings ratio of -5.26 and a beta of -0.53. The firm has a 50-day moving average of $15.78 and a 200 day moving average of $12.76. The company has a current ratio of 2.21, a quick ratio of 2.21 and a debt-to-equity ratio of 0.01. Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.58) earnings per share (EPS) for the quarter. The firm had revenue of $0.24 million for the quarter. Hedge Funds Weigh In On Coeptis TherapeuticsA hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 8,000 shares of the company's stock, valued at approximately $140,000. Coeptis Therapeutics makes up about 0.0% of Yorkville Advisors Global LP's investment portfolio, making the stock its 24th biggest position. Yorkville Advisors Global LP owned 0.17% of Coeptis Therapeutics at the end of the most recent quarter. 13.88% of the stock is owned by institutional investors and hedge funds. Coeptis Therapeutics Company Profile (Get Free Report)Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.Featured StoriesFive stocks we like better than Coeptis TherapeuticsBest Stocks Under $10.00 Market Momentum: 3 Stocks Poised for Major BreakoutsRide Out The Recession With These Dividend Kings 3 Reasons Casey’s General Stores Will Continue Trending HigherWhat Are Dividend Challengers?Golden Cross Alert: 3 Stocks With Major Upside PotentialThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Coeptis Therapeutics Right Now?Before you consider Coeptis Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coeptis Therapeutics wasn't on the list.While Coeptis Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here